Therapies for Patients With HR-Positive Breast Cancer

April 23, 2014
Hyman B. Muss, MD

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, gives an overview of therapies for patients with HR-positive breast cancer.

Clinical Pearls

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, gives an overview of therapies for patients with HR-positive breast cancer. Muss discussed this topic in a talk at the31st Annual Miami Breast Cancer Conference®.

  • Exemestane can extend the time of disease control substantially with some risk of toxicities.
  • Data have shown that biologic agents and traditional endocrine therapy can work together for possibly much better outcomes.
  • Pharmaceutical companies have begun to develop new compounds and analyze models of enhancing endocrine therapy with biologic agents.